- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
Roche provides update on two Phase III studies of lebrikizumab in asthma
29 February 2016 • Author: Victoria White
Roche has announced top-line results from its LAVOLTA I & II studies that evaluated the efficacy and safety of lebrikizumab in people with severe asthma.
LAVOLTA I and II are two identical, randomised, multicentre, placebo-controlled phase III studies designed to evaluate the efficacy and safety of lebrikizumab in people with severe asthma that is uncontrolled despite standard-of-care treatment with an inhaled corticosteroid and a second controller medication. The studies together included more than 2,100 people across 28 countries. The primary endpoint of both studies was the rate of asthma exacerbations over 52 weeks. The evaluation of the primary and secondary endpoints was based on a subgroup of people with higher levels of serum periostin or blood eosinophils.
LAVOLTA I met its primary endpoint, showing a significant reduction in the rate of asthma exacerbations in people with higher levels of serum periostin or blood eosinophils. In addition, this study demonstrated a significant improvement in lung function as measured by forced expiratory volume in one second (FEV1). The observed effect in the primary and secondary endpoints, however, was less than seen in the lebrikizumab Phase II trials.
In contrast, the exacerbation reduction results observed in LAVOLTA II did not meet statistical significance. No new safety signals were observed in either study.
Data require ‘further interpretation’, says Roche
“We were hopeful these identical studies would confirm the Phase II results because there is still a significant unmet need for people with severe asthma,” said Sandra Horning, M.D., Chief Medical Officer and Head of Global Product Development at Roche. “These data require further interpretation and analyses are ongoing to better understand the results and determine next steps.”
Roche has said that results from the studies will be submitted for presentation at forthcoming medical meetings.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics